Jundishapur Journal of Microbiology

Published by: Kowsar

Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections

Bahareh Moazen 1 , Elahe Ebrahimi 3 and Foroogh Nejatollahi 2 , 3 , *
Authors Information
1 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Department of Immunology, Recombinant Antibody Laboratory, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: March 01, 2016, 9 (3); e16241
  • Published Online: March 15, 2016
  • Article Type: Research Article
  • Received: December 7, 2013
  • Revised: July 18, 2014
  • Accepted: July 23, 2014
  • DOI: 10.5812/jjm.16241

To Cite: Moazen B, Ebrahimi E, Nejatollahi F. Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections, Jundishapur J Microbiol. 2016 ; 9(3):e16241. doi: 10.5812/jjm.16241.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Freeman RJ. The 'indirect' effects of cytomegalovirus infection. Am J Transplant. 2009; 9(11): 2453-8[DOI][PubMed]
  • 2. Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med. 2008; 36(12): 3145-50[DOI][PubMed]
  • 3. Carrillo Esper R. [Citomegalovirus reactivation in critical ill intensive care patients]. Gac Med Mex. 2011; 147(2): 159-62[PubMed]
  • 4. Medina JC, Pérez-Sartori G, Caltenco-Serrano R, María Aguado J. Immunologic Response and Pathogenic Mechanisms of Cytomegalovirus Infection in Transplant Recipients. Trends Transplant. 2009; 3(2): 103-12
  • 5. Slyker JA, Lohman-Payne BL, John-Stewart GC, Maleche-Obimbo E, Emery S, Richardson B, et al. Acute cytomegalovirus infection in Kenyan HIV-infected infants. AIDS. 2009; 23(16): 2173-81[DOI][PubMed]
  • 6. Gerna G, Lilleri D, Furione M, Baldanti F. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection. New Microbiol. 2011; 34(3): 229-54[PubMed]
  • 7. Puchhammer-Stöckl E, Görzer I. Human cytomegalovirus: an enormous variety of strains and their possible clinical significance in the human host. Future Virology. 2011; 6(2): 259-71[DOI]
  • 8. Knipe DM, Howley PM. Fields' virology. 2007;
  • 9. Elliott SP. Congenital cytomegalovirus infection: an overview. Infect Disord Drug Targets. 2011; 11(5): 432-6[PubMed]
  • 10. McGregor A. Current and new cytomegalovirus antivirals and novel animal model strategies. Inflamm Allergy Drug Targets. 2010; 9(4): 286-99[PubMed]
  • 11. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010; 6(12): 711-21[DOI][PubMed]
  • 12. Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm. 2010; 67(17): 1417-25[DOI][PubMed]
  • 13. Van den Bosch GA, Ponsaerts P, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF. Cellular immunotherapy for cytomegalovirus and HIV-1 infection. J Immunother. 2006; 29(2): 107-21[DOI][PubMed]
  • 14. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J. 2002; 21(2): 133-8[PubMed]
  • 15. Bergallo M, Costa C, Gambarino S, Tornicelli A, Astegiano S, Terlizzi ME, et al. Human cytomegalovirus glycoprotein B genotyping from bronchoalveolar lavage specimens. Can J Microbiol. 2011; 57(4): 273-7[DOI][PubMed]
  • 16. Nejatollahi F, Hodgetts SJ, Vallely PJ, Burnie JP. Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol Med Microbiol. 2002; 34(3): 237-44[PubMed]
  • 17. Nejatollahi F, Malek-Hosseini Z, Mehrabani D. Development of single chain antibodies to P185 tumor antigen. Iran Red Crescent Med J. 2008; 10(4): 298-302
  • 18. Weisser NE, Hall JC. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv. 2009; 27(4): 502-20[DOI][PubMed]
  • 19. Zhang H. Empowering scFv with effector cell functions for improved anticancer therapeutics. Oncoimmunology. 2013; 2(6)[DOI][PubMed]
  • 20. Nejatollahi F, Jaberipour M, Asgharpour M. Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells. Tumour Biol. 2014; 35(8): 7887-95[DOI][PubMed]
  • 21. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002; 13(6): 603-8[PubMed]
  • 22. Baek H, Suk KH, Kim YH, Cha S. An improved helper phage system for efficient isolation of specific antibody molecules in phage display. Nucleic Acids Res. 2002; 30(5)[PubMed]
  • 23. Ishibashi K, Tokumoto T, Shirakawa H, Hashimoto K, Ikuta K, Kushida N, et al. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors. Transpl Infect Dis. 2011; 13(3): 318-23[DOI][PubMed]
  • 24. Singh J, Compton T. Characterization of a panel of insertion mutants in human cytomegalovirus glycoprotein B. J Virol. 2000; 74(3): 1383-92[PubMed]
  • 25. Krauss S, Kaps J, Czech N, Paulus C, Nevels M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J Virol. 2009; 83(24): 12854-70[DOI][PubMed]
  • 26. Axelsson F, Adler SP, Lamarre A, Ohlin M. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine. 2007; 26(1): 41-6[DOI][PubMed]
  • 27. Lillo AM, Ayriss JE, Shou Y, Graves SW, Bradbury AR, Pavlik P. Development of phage-based single chain Fv antibody reagents for detection of Yersinia pestis. PLoS One. 2011; 6(12)[DOI][PubMed]
  • 28. Krishnaswamy S, Kabir ME, Rahman MM, Miyamoto M, Furuichi Y, Komiyama T. Isolation and characterization of recombinant single chain fragment variable anti-idiotypic antibody specific to Aspergillus fumigatus membrane protein. J Immunol Methods. 2011; 366(1-2): 60-8[DOI][PubMed]
  • 29. Thathaisong U, Maneewatch S, Kulkeaw K, Thueng-In K, Poungpair O, Srimanote P, et al. Human monoclonal single chain antibodies (HuScFv) that bind to the polymerase proteins of influenza A virus. Asian Pac J Allergy Immunol. 2008; 26(1): 23-35[PubMed]
  • 30. Meyer T, Stratmann-Selke J, Meens J, Schirrmann T, Gerlach GF, Frank R, et al. Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Vet Microbiol. 2011; 147(1-2): 162-9[DOI][PubMed]
  • 31. Urushibata Y, Itoh K, Ohshima M, Seto Y. Generation of Fab fragment-like molecular recognition proteins against staphylococcal enterotoxin B by phage display technology. Clin Vaccine Immunol. 2010; 17(11): 1708-17[DOI][PubMed]
  • 32. Zhang JL, Gou JJ, Zhang ZY, Jing YX, Zhang L, Guo R, et al. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen. Hepatobiliary Pancreat Dis Int. 2006; 5(2): 237-41[PubMed]
  • 33. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, et al. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004; 64(2): 103-11[DOI][PubMed]
  • 34. Jun F, Minhuan L, Yadan M, Yaping H, Hanying L, Jianhua H, et al. Development of two potential diagnostic monoclonal antibodies against human cytomegalovirus glycoprotein B. Braz J Med Biol Res. 2012; 45(7): 583-90[PubMed]
  • 35. Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, et al. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience. Liver Transpl. 2012; 18(12): 1448-55[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments